Skip to Main Content

True to its word, the pharmaceutical industry trade group has revised its membership criteria in a bid to deflect stinging criticism that too many drug makers aggressively raise prices, but issue empty promises about investing in research and development to produce needed medicines.

Going forward, companies will now have to invest an average of 10 percent of global sales on R&D and spend at least $200 million annually on R&D over a three-year period, in order to be a member of the Pharmaceutical Research & Manufacturers of America. Nearly two dozen members overall will not make the cut.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!